Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells

This protocol enables the testing of drugs against infection of epithelial cells with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), using pseudo-typed replication deficient vesicular stomatitis virus particles (pp-VSV) presenting the SARS-CoV-2 spike protein. After treating human vol...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Katrin Anne, Carpinteiro, Alexander, Hoffmann, Markus, Pöhlmann, Stefan, Kornhuber, Johannes, Gulbins, Erich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857112/
https://www.ncbi.nlm.nih.gov/pubmed/33558862
http://dx.doi.org/10.1016/j.xpro.2021.100356
_version_ 1783646382343585792
author Becker, Katrin Anne
Carpinteiro, Alexander
Hoffmann, Markus
Pöhlmann, Stefan
Kornhuber, Johannes
Gulbins, Erich
author_facet Becker, Katrin Anne
Carpinteiro, Alexander
Hoffmann, Markus
Pöhlmann, Stefan
Kornhuber, Johannes
Gulbins, Erich
author_sort Becker, Katrin Anne
collection PubMed
description This protocol enables the testing of drugs against infection of epithelial cells with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), using pseudo-typed replication deficient vesicular stomatitis virus particles (pp-VSV) presenting the SARS-CoV-2 spike protein. After treating human volunteers with amitriptyline, an approved antidepressant and inhibitor of the acid sphingomyelinase, freshly isolated nasal epithelial cells were infected ex vivo and infection levels were quantified. This protocol offers the possibility to rapidly test the efficacy of potential drugs in the fight against COVID-19. For complete details on the use and execution of this protocol, please refer to Carpinteiro et al. (2020).
format Online
Article
Text
id pubmed-7857112
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78571122021-02-04 Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells Becker, Katrin Anne Carpinteiro, Alexander Hoffmann, Markus Pöhlmann, Stefan Kornhuber, Johannes Gulbins, Erich STAR Protoc Protocol This protocol enables the testing of drugs against infection of epithelial cells with SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), using pseudo-typed replication deficient vesicular stomatitis virus particles (pp-VSV) presenting the SARS-CoV-2 spike protein. After treating human volunteers with amitriptyline, an approved antidepressant and inhibitor of the acid sphingomyelinase, freshly isolated nasal epithelial cells were infected ex vivo and infection levels were quantified. This protocol offers the possibility to rapidly test the efficacy of potential drugs in the fight against COVID-19. For complete details on the use and execution of this protocol, please refer to Carpinteiro et al. (2020). Elsevier 2021-02-03 /pmc/articles/PMC7857112/ /pubmed/33558862 http://dx.doi.org/10.1016/j.xpro.2021.100356 Text en © 2021 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Protocol
Becker, Katrin Anne
Carpinteiro, Alexander
Hoffmann, Markus
Pöhlmann, Stefan
Kornhuber, Johannes
Gulbins, Erich
Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
title Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
title_full Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
title_fullStr Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
title_full_unstemmed Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
title_short Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells
title_sort ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing sars-cov-2 infection of nasal epithelial cells
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857112/
https://www.ncbi.nlm.nih.gov/pubmed/33558862
http://dx.doi.org/10.1016/j.xpro.2021.100356
work_keys_str_mv AT beckerkatrinanne exvivoassaytoevaluatetheefficacyofdrugstargetingsphingolipidsinpreventingsarscov2infectionofnasalepithelialcells
AT carpinteiroalexander exvivoassaytoevaluatetheefficacyofdrugstargetingsphingolipidsinpreventingsarscov2infectionofnasalepithelialcells
AT hoffmannmarkus exvivoassaytoevaluatetheefficacyofdrugstargetingsphingolipidsinpreventingsarscov2infectionofnasalepithelialcells
AT pohlmannstefan exvivoassaytoevaluatetheefficacyofdrugstargetingsphingolipidsinpreventingsarscov2infectionofnasalepithelialcells
AT kornhuberjohannes exvivoassaytoevaluatetheefficacyofdrugstargetingsphingolipidsinpreventingsarscov2infectionofnasalepithelialcells
AT gulbinserich exvivoassaytoevaluatetheefficacyofdrugstargetingsphingolipidsinpreventingsarscov2infectionofnasalepithelialcells

Ejemplares similares